These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 20648579)

  • 1. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.
    Ashikaga T; Krag DN; Land SR; Julian TB; Anderson SJ; Brown AM; Skelly JM; Harlow SP; Weaver DL; Mamounas EP; Costantino JP; Wolmark N;
    J Surg Oncol; 2010 Aug; 102(2):111-8. PubMed ID: 20648579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.
    Lucci A; McCall LM; Beitsch PD; Whitworth PW; Reintgen DS; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Giuliano AE;
    J Clin Oncol; 2007 Aug; 25(24):3657-63. PubMed ID: 17485711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sentinel lymph node biopsy in breast cancer: cure and survival are paramount.
    Moffat FL
    J Surg Oncol; 2010 Aug; 102(2):109-10. PubMed ID: 20648578
    [No Abstract]   [Full Text] [Related]  

  • 4. Complication rates in patients with negative axillary nodes 10 years after local breast radiotherapy after either sentinel lymph node dissection or axillary clearance.
    Wernicke AG; Shamis M; Sidhu KK; Turner BC; Goltser Y; Khan I; Christos PJ; Komarnicky-Kocher LT
    Am J Clin Oncol; 2013 Feb; 36(1):12-9. PubMed ID: 22134519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer.
    Swenson KK; Nissen MJ; Ceronsky C; Swenson L; Lee MW; Tuttle TM
    Ann Surg Oncol; 2002 Oct; 9(8):745-53. PubMed ID: 12374657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group.
    Husted Madsen A; Haugaard K; Soerensen J; Bokmand S; Friis E; Holtveg H; Peter Garne J; Horby J; Christiansen P
    Breast; 2008 Apr; 17(2):138-47. PubMed ID: 17928226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 10-year follow-up of treatment outcomes in patients with early stage breast cancer and clinically negative axillary nodes treated with tangential breast irradiation following sentinel lymph node dissection or axillary clearance.
    Wernicke AG; Goodman RL; Turner BC; Komarnicky LT; Curran WJ; Christos PJ; Khan I; Vandris K; Parashar B; Nori D; Chao KS
    Breast Cancer Res Treat; 2011 Feb; 125(3):893-902. PubMed ID: 20853176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma.
    Schrenk P; Rieger R; Shamiyeh A; Wayand W
    Cancer; 2000 Feb; 88(3):608-14. PubMed ID: 10649254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial.
    Giuliano AE; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Hunt KK; Morrow M; Ballman K
    Ann Surg; 2010 Sep; 252(3):426-32; discussion 432-3. PubMed ID: 20739842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arm morbidity of axillary dissection with sentinel node biopsy versus delayed axillary dissection.
    Ballal H; Hunt C; Bharat C; Murray K; Kamyab R; Saunders C
    ANZ J Surg; 2018 Sep; 88(9):917-921. PubMed ID: 29392828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A longitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection.
    Kootstra JJ; Hoekstra-Weebers JE; Rietman JS; de Vries J; Baas PC; Geertzen JH; Hoekstra HJ
    Ann Surg Oncol; 2010 Sep; 17(9):2384-94. PubMed ID: 20221902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer.
    Rietman JS; Dijkstra PU; Geertzen JH; Baas P; de Vries J; Dolsma WV; Groothoff JW; Eisma WH; Hoekstra HJ
    Ann Surg Oncol; 2004 Nov; 11(11):1018-24. PubMed ID: 15525832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shoulder-arm morbidity in patients with sentinel node biopsy and complete axillary dissection--data from a prospective randomised trial.
    Helms G; Kühn T; Moser L; Remmel E; Kreienberg R
    Eur J Surg Oncol; 2009 Jul; 35(7):696-701. PubMed ID: 18838245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.
    Giuliano AE; Hunt KK; Ballman KV; Beitsch PD; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; McCall LM; Morrow M
    JAMA; 2011 Feb; 305(6):569-75. PubMed ID: 21304082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morbidity after conventional dissection of axillary lymph nodes in breast cancer patients.
    Soares EW; Nagai HM; Bredt LC; da Cunha AD; Andrade RJ; Soares GV
    World J Surg Oncol; 2014 Mar; 12():67. PubMed ID: 24670000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node.
    Khakpour N; Hunt KK; Kuerer HM; Yi M; Meric-Bernstam F; Ross MI; Lucci A
    Am J Surg; 2005 Oct; 190(4):598-601. PubMed ID: 16164930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term morbidity of the upper limb after sentinel lymph node biopsy or axillary lymph node dissection for Stage I or II breast carcinoma.
    Rietman JS; Dijkstra PU; Geertzen JH; Baas P; De Vries J; Dolsma W; Groothoff JW; Eisma WH; Hoekstra HJ
    Cancer; 2003 Aug; 98(4):690-6. PubMed ID: 12910511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.